MARKET

LFCR

LFCR

Lifecore Biomedical Inc
NASDAQ
8.04
+0.14
+1.77%
Closed 16:01 12/06 EST
OPEN
7.85
PREV CLOSE
7.90
HIGH
8.10
LOW
7.83
VOLUME
105.85K
TURNOVER
--
52 WEEK HIGH
12.04
52 WEEK LOW
7.81
MARKET CAP
237.95M
P/E (TTM)
-4.6799
1D
5D
1M
3M
1Y
5Y
$5 Million Bet On Lifecore Biomedical? Check Out These 4 Stocks Insiders Are Buying
Benzinga · 11/30 11:55
Lifecore Biomedical Raises Capital for Growth with Existing Stockholder
$5 million PIPE supports near-term capital needs to meet equipment milestonesCHASKA, Minn., Nov. 25, 2022 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“...
GlobeNewswire · 11/25 21:50
Landec Corporation (NASDAQ:LFCR) is largely controlled by institutional shareholders who own 51% of the company
A look at the shareholders of Landec Corporation ( NASDAQ:LFCR ) can tell us which group is most powerful. We can see...
Simply Wall St. · 11/17 18:17
Lifecore Biomedical CEO Hall on Rebranding, New Ticker on Nasdaq
Lifecore Biomedical CEO James G. Hall By Jarrett Banks IPO Edge: Can you give me a short description of what Lifecore does? Lifecore Biomedical is a fully integrated contract development […]
IPO-Edge.com · 11/15 13:30
Lifecore Biomedical Announces Completion of Corporate Name Change
Common stock expected to begin trading tomorrow under new Nasdaq ticker symbol “LFCR” Lifecore global headquarters relocated to Chaska, MN Launches new investor relations website: ir.lifecore.com CHASKA, Minn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lifecore Bi...
GlobeNewswire · 11/14 14:02
Landec Expects To Change Corporate Name To Lifecore Biomedical And Ticker Symbol To "LFCR" On November 14
Benzinga · 11/01 12:14
--Barrington Research Lowers Landec's Price Target to $12 From $14, Maintains Outperform Rating
--Barrington Research Lowers Landec's Price Target to $12 From $14, Maintains Outperform Rating
MT Newswires · 10/07 10:08
Landec (LNDC) Reports Q1 Loss, Tops Revenue Estimates
Landec (LNDC) delivered earnings and revenue surprises of -166.67% and 1.89%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 10/06 12:35
More
About LFCR
Lifecore Biomedical, Inc., formerly Landec Corporation (Landec), is a fully integrated contract development and manufacturing organization (CDMO). The Company offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials, as well as the manufacture of pharmaceutical-grade Hyaluronic Acid. It provides complete CDMO services for injectable pharmaceuticals and medical devices. The Company’s services include sodium hyaluronate, development, manufacturing, and analytical services. It offers a range of average molecular weights and custom modifications for research and development (R&D), clinical, and commercial applications. The Company’s therapeutic applications include drug delivery, biomaterials, ophthalmology, orthopedics, aesthetics, oncology, and pain management. Its development capabilities include formulation, sterile filtration, filling, packaging, testing, and secondary sterilization.

Webull offers kinds of Lifecore Biomedical Inc stock information, including NASDAQ:LFCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LFCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LFCR stock methods without spending real money on the virtual paper trading platform.